No Data
Hong Kong stocks movement | Simcere pharma (02096) surged over 12% with trading volume exceeding 0.2 billion Hong Kong dollars. The company is expected to welcome multiple catalysts.
Simcere pharma (02096) surged over 12% in volume, as of the time of this report, it rose by 12.38%, priced at 6.99 Hong Kong dollars, with a trading volume of 0.233 billion Hong Kong dollars.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
Bocom Intl: The tenth batch of national purchases started reporting volumes. Bullish on sector sentiment improvement + valuation repair after the conclusion of medical insurance negotiations.
bocom intl highlights Akeso (09926), Simcere Pharma (02096), Legend Biotech (LEGN.US), Silver Cresting Bright Prosperity-B (01952), Hutchmed (China) Pharmaceuticals (00013), etc.
simcere pharma (02096.HK) spent 9.935 million Hong Kong dollars to repurchase 1.485 million shares on November 6th.
Glory Medical November 6th | simcere Pharma (02096.HK) announced that on November 6th, it spent 9.935 million Hong Kong dollars to repurchase 1.485 million shares.
Hong Kong stock concept tracking | The end of medical insurance negotiations is very encouraging for innovative drugs to be included in medical insurance at reasonable prices (with concept stocks)
The on-site negotiation and bidding stages for the adjustment of the national medical insurance pharmaceutical catalog in 2024 officially ended recently.
Simcere Pharmaceutical Group Limited's (HKG:2096) Business And Shares Still Trailing The MarketNo Data
No Data
